Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096914 | 0.96 | HPGD (0.62) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL13779779 | 0.96 | HPGD (0.62) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL15107851 | 0.96 | HPGD (0.62) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL19852527 | 0.96 | HPGD (0.62) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL21183487 | 0.95 | HPGD (0.64) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL21142470 | 0.93 | HPGD (0.67) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL215146 | 0.89 | MEN1 (0.56) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL30862413 | 0.89 | MEN1 (0.56) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL1068107 | 0.89 | MEN1 (0.56) | HPGDEPHX1USP2SMN1; SMN2MEN1 | |
| SCHEMBL190483 | 0.89 | MEN1 (0.56) | HPGDEPHX1USP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HPGD 3843/4885EPHX1 1684/4885USP2 141/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HPGD 3843/4885EPHX1 1684/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.